← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Centessa Pharmaceuticals plc: Revenue grew to $15M from $0. Net loss narrowed to $198M from $236M. Free cash flow outflow widened to $194M from $142M. Operating margin was -1384.61%. Centessa Pharmaceuticals plc's annual comparison also shows the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew to $15M from $0OK
- Profitability — Net loss narrowed to $198M from $236MOK
- Cash flow — Free cash flow outflow widened to $194M from $142MWatch
- Margins — Operating margin was -1384.61%Note
- Accounting — Distress-range screen needs contextWatch
- Insiders — 0 purchases and 24 salesWatch
Business
Our most advanced product candidate, cleminorexton (formerly referred to as ORX750), is a novel, oral, highly potent and selective orexin receptor 2 (OX2R) agonist in late-stage clinical development for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).
Where the revenue comes from
Fiscal 2025, as Centessa Pharmaceuticals plc reports it. History and quarterly detail are in the app.
Leadership changes
From Centessa Pharmaceuticals plc's own filings, the day they're filed.
- Saurabh Saha · Chief Executive Officer · departureeff. 2026-01-01
- Saurabh Saha · CEO · departureeff. 2026-01-01
- Raphael Deferiere · Chief Accounting Officer · appointmenteff. 2025-05-27
Latest filings
- 8-K · Company announcement2026-06-24
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-05-22
- 10-Q · Quarterly report2026-05-05
- DEF 14A · Annual proxy (pay & governance)2026-04-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Centessa Pharmaceuticals plc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.